NCT02814500

DP-R212 Pharmacokinetic Study Phase I

DP-R212 Pharmacokinetic Study Pharmacokinetic Characteristics of DP-R212 in Comparison to Each Component Coadministered in Healthy Volunteers

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Alvogen Korea · Industry
• Sex: All
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212

Detailed description

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212, a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	DP-R212	Investigational product is prescribed to all of randomized subjects
DRUG	Amlodipine	Investigational product is prescribed to all of randomized subjects
DRUG	Rosuvastatin	Investigational product is prescribed to all of randomized subjects

Timeline

• Start date: 2016-07-01
• Primary completion: 2016-09-01
• Completion: 2016-09-01
• First posted: 2016-06-27
• Last updated: 2016-06-27